Skip to content

About this survey


Thank you for participating.
This independent study by PatientView looks at the corporate reputation of the pharmaceutical industry (and that of 47 pharmaceutical companies) during 2025. 3 new pharmaceutical companies have been included for this 2025 survey.

You will be entitled to a free copy of the full results upon publication (April 2026), if you wish to receive them.
Note about the survey format:
  • If you are using a mobile/cell to answer the questionnaire, the survey is more easily completed when the mobile/cell is in LANDSCAPE.
This survey has 8 questions about your organisation, and 12 main questions. When you reach the end of the questionnaire, please click the “Submit” button to send it.

If you have any queries about this survey, the email contact is at the end of the survey.
EIGHT PROFILING QUESTIONS

These profiling questions will help us understand the TYPES of organisations answering the survey, and allow us to make more sense of the results.

a.) Please note below (in your own choice of words) your organisation’s MAIN SPECIALTY.
b.) In which COUNTRY is your organisation based or headquartered?

(If you are a patient group with international scope, please respond on behalf of the country in which you, as a respondent, reside.)

Please select your country from the menu below.
c.) What is the GEOGRAPHIC REACH of your organisation?
d.) In the last 12 months, approximately HOW MANY PATIENTS did your organisation actively support and serve?
e.) Does your organisation represent PATIENT INTERESTS to REGULATORS that are responsible for deciding (or advising on) drug pricing?
f.) Below is a list of 47 pharma companies worldwide
(including 3 companies new for this 2025 survey).

Can you indicate the companies with which your organisation has WORKED or co-operated?

g.) If your organisation WORKS or CO-OPERATES with pharma companies:
What are the MAIN TYPES of working or co-operating relationships your organisation has with pharma companies?
h.) The same list of 47 pharma companies.

For the companies with which your organisation does not work:
Can you indicate the companies with which your organisation is FAMILIAR?

Please take the word ‘familiar’ to mean:
“Feeling knowledgeable enough about the company to be able to comment on its activities and products.”
QUESTIONS ON CORPORATE REPUTATION

For the purposes of this survey, please regard the phrase ‘corporate reputation’ to be defined as:

“The extent to which pharmaceutical companies are meeting the expectations of patients and patient groups.”

The survey has 12 main questions

Please skip any question that you cannot answer (or are irrelevant to your organisation).

FIRST, two questions about ...
the corporate reputation of the pharma industry as a whole

Question 1 of 12.
How does your organisation rate the corporate reputation of the following healthcare sectors in 2025?
Excellent.
Good.
Fair.
Poor.
I do not know.
Biotechnology companies.
Generic drug manufacturers.
Health insurers (for-profit).
Health insurers (not-for-profit).
Medical-device companies.
Pharmaceutical companies (multinational).
Pharmacy Benefit Managers (PBMs)—if relevant in your country.
Private-sector healthcare services.
Retail pharmacists.
Question 2 of 12.
How “good” or “bad” do you think the pharmaceutical industry as a whole has been in 2025 at carrying out the following activities (all of which influence the industry’s corporate standing with patients and patient groups)?
Excellent.
Good.
Fair.
Poor.
I do not know.
Having a patient-centred strategy.
Providing high-quality information for patients.
Ensuring patient safety.
Being innovative.
Making products that are of benefit to patients.
Being transparent about company pricing policies.
Being transparent by sharing clinical data.
Being transparent by disclosing the funding of stakeholders (such as doctors or patient groups).
Acting with integrity.
Working in partnership with patient groups.
Providing patients with more services than just the provision of medicines.
Fair pricing policies.
Engaging patients/patient groups in company drug R&D (research and development).
Helping more patients gain access to medicines.
Please click “Next”, below, to move on to the company-specific questions.
Privacy & Cookie Notice